Cancer
Ambry Genetics' CARE Program Validated as Accurate Tool for Hereditary Cancer Risk Assessment
A newly published peer-reviewed study in the Journal of the National Comprehensive Cancer Network (NCCN) validates the Ambry CARE Program's utility as a digital risk assessment tool with 99.5% accuracy in identifying individuals at risk for hereditary cancer. The study assessed the program's ability to